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Abstract
Background: In south-eastern Senegal, malaria and onchocerciasis are co-endemic. Onchocerciasis in this region
has been controlled by once or twice yearly mass drug administration (MDA) with ivermectin (IVM) for over fifteen
years. Since laboratory-raised Anopheles gambiae s.s. are susceptible to ivermectin at concentrations found in
human blood post-ingestion of IVM, it is plausible that a similar effect could be quantified in the field, and that
IVM might have benefits as a malaria control tool.
Methods: In 2008 and 2009, wild-caught blood fed An. gambiae s.l. mosquitoes were collected from huts of three
pairs of Senegalese villages before and after IVM MDAs. Mosquitoes were held in an insectary to assess their
survival rate, subsequently identified to species, and their blood meals were identified. Differences in mosquito
survival were statistically analysed using a Glimmix model. Lastly, changes in the daily probability of mosquito
survivorship surrounding IVM MDAs were calculated, and these data were inserted into a previously developed,
mosquito age-structured model of malaria transmission.
Results: Anopheles gambiae s.s. (P < 0.0001) and Anopheles arabiensis (P = 0.0191) from the treated villages had
significantly reduced survival compared to those from control villages. Furthermore, An gambiae s.s. caught 1-6
days after MDA in treated villages had significantly reduced survival compared to control village collections
(P = 0.0003), as well as those caught pre-MDA (P < 0.0001) and >7 days post-MDA (P < 0.0001). The daily
probability of mosquito survival dropped >10% for the six days following MDA. The mosquito age-structured
model of malaria transmission demonstrated that a single IVM MDA would reduce malaria transmission (Ro) below
baseline for at least eleven days, and that repeated IVM MDAs would result in a sustained reduction in malaria Ro.
Conclusions: Ivermectin MDA significantly reduced the survivorship of An. gambiae s.s. for six days past the date
of the MDA, which is sufficient to temporarily reduce malaria transmission. Repeated IVM MDAs could be a novel
and integrative malaria control tool in areas with seasonal transmission, and which would have simultaneous
impacts on neglected tropical diseases in the same villages.
Background
Every year, an estimated 500 million people are afflicted
with malaria worldwide, killing more than one million
people, most of whom are children in sub-Saharan
Africa [1,2]. Current control measures for preventing
malaria transmission in Africa focus on the use of long-
lasting insecticide-treated nets (LLITNs) treated with
pyrethroids and indoor residual spraying (IRS) with
organochlorines and pyrethroids. Both of these control
methods have proven effective as a means for reducing
Plasmodium transmission by endophagic malaria vectors
but are potentially threatened by vector resistance to the
currently used insecticides [3]. The development of
novel methods to reduce Plasmodium transmission that
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measures, as well as other health priorities, is critical.
In 1987, ivermectin (IVM) was registered for human
use for the control of onchocerciasis [4] and later for
lymphatic filariasis [5]. Its primary effects are against
microfilariae in the human body, which are the trans-
missible parasite stages of these diseases. Ivermectin has
been used extensively since the mid-1990’s in mass drug
administration (MDA) campaigns across Africa by the
African Programme for Onchocerciasis Control (APOC)
[6] and the Global Program to Eliminate Lymphatic
Filariasis (GPELF) [5]. Annually, more than 80 million
people across the tropics are treated with IVM by
MDA [7].
Previous in vitro and animal studies demonstrated that
IVM can reduce the survivorship of multiple mosquito
species after ingesting the drug in blood [8-11]. Wilson
[12] reviewed these and other studies and suggested that
the avermectins might impart their strongest impact on
disease transmission by reducing vector longevity
thereby reducing vectorial capacity. Concentrations of
IVM found in human venous plasma after standard
IVM MDA (150 μg/kg) reduced the survivorship and re-
blood feeding frequency of laboratory-reared Anopheles
gambiae s.s., which are the two most critical variables in
models of vectorial capacity [13]. Two studies have
directly blood fed laboratory-reared Anopheles spp. mos-
quitoes on humans who have ingested IVM. Foley et al
[14] reported reduced Anopheles farauti survivorship
when mosquitoes fed on one person who ingested
250 μg/kg of IVM. Chaccour et al [15] found that An.
gambiae s.s. blood fed on humans one day after they
h a di n g e s t e d2 0 0μg/kg of IVM had significantly
reduced survivorship, but the effect was not apparent
fourteen days post-ingestion. To date, the only field
based study on the effects of IVM against wild mosqui-
toes was performed in Papua New Guinea and focused
on lymphatic filariasis control. Bockarie et al [16]
demonstrated that MDA with IVM (400 μg/kg) in com-
bination with diethylcarbamazine citrate (6 mg/kg) in
one village reduced the survivorship of wild Anopheles
punctulatus up to four days after MDA. In another vil-
lage, MDA with IVM (400 μg/kg) alone reduced the sur-
vivorship of wild An. punctulatus captured the day after
MDA [16].
The goal of this study was to determine if IVM MDA
of humans in Senegal for onchocerciasis control could
simultaneously reduce the survivorship of wild African
malaria vectors, and if so, for how long this effect would
occur, and to model this effect on malaria transmission.
Villages in south-eastern Senegal have been treated once
o rt w i c ey e a r l yw i t hI V MM D A( 1 5 0μg/kg) for oncho-
cerciasis eradication for over fifteen years [17]. This
same region has hyperendemic malaria transmission
[18,19] and has an abundant and diverse Anopheles
malaria vector fauna [20]. In 2008 and 2009, blood-fed
Anopheles spp. were captured from inside peoples’ huts
before and after IVM MDA in three replicate pairs of
villages in south-eastern Senegal. Survivorship of the
mosquitoes was assessed by holding them in a field
insectary for five days. Mosquito survivorship data were
then incorporated into a modified previously-developed
model [21] to evaluate the potential of IVM to reduce
malaria transmission. The results demonstrate that IVM
MDA reduces the survivorship of wild An. gambiae s.s.
and that this reduction in survivorship should be suffi-
cient to reduce malaria transmission.
Methods
Study site
The study was conducted in the villages of Bounda-
coundi, Damboucoye, Nathia, Ibel and Ndebou, all in
the Sudano-Guinean zone of rural south-eastern Sene-
gal. The five villages are located along a 15 km stretch
of road heading west out of Kedougou. Most of the peo-
p l ei nt h i sa r e aa r es u b s i s t e n c ef a r m e r s .T h e yl i v ei n
extended family compounds with 2-10 sleeping huts,
and cultivate maize, sorghum and groundnuts between
these compounds and in separate fields outside the vil-
lage. Cattle, sheep, goats, dogs, and chickens are the pri-
mary domesticated animals in the villages. In 2008, two
villages were sampled, Ibel and Ndebou. Ibel was treated
by MDA with 150 μg/kg of IVM (Mectizan™, Merck &
Co., Inc) on August 8, 2008, while Ndebou was not trea-
ted and served as the paired control village. In 2009, two
pairs of villages were sampled. Ndebou and Bounda-
coundi were the first pair of villages sampled and MDA
occurred on August 6, 2009 in Ndebou, with Bounda-
coundi serving as the control. Damboucoye and Nathia
were the second pair of villages sampled and MDA
occurred on October 11, 2009 in Damboucoye, with
Nathia serving as the control. MDA was coordinated by
APOC in Senegal and the Senegalese Ministry of Health,
and performed through community-directed treatment
by the local nurses. Permission to conduct mosquito
sampling surrounding these MDAs was granted first by
the Senegalese Ministry of Health and then by the resi-
dents of each village. The study was also reviewed by
the Colorado State University Institutional Review Board
prior to being conducted.
Mosquito collections
Indoor resting, wild, blood fed Anopheles mosquitoes
were collected in the morning from huts people had
slept in the previous night using backpack aspirators
(John W. Hock, Gainesville, FL, USA). After capture,
Anopheles mosquitoes were transferred by mouth aspira-
tors from backpack aspirator cups to 473 ml cardboard
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labelled and designated by village, date collected, and
the specific hut from which mosquitoes were collected.
Containers were placed into a large basket and two
moist towels were placed over the top of the basket to
keep the mosquitoes humid and cool. Immediately fol-
lowing morning aspirations, the mosquitoes were trans-
ported back to the insectary in Bandafassi (2008) or
Kedougou (2009) and maintained on shelves. Insectaries
were designated rooms of houses and had screened and
slatted windows so that they naturally fluctuated with
the ambient temperature and humidity. Temperature
and humidity within the insectary ranged from (27 - 30°
C) and (66 - 86%). Any dead, non-blood fed, or non-
Anopheles mosquitoes were removed from the contain-
ers upon placement in the insectary. The containers had
a moistened sponge and raisins placed on top to serve
as water and sugar sources for the mosquitoes. Survivor-
ship was checked daily at 12:00 pm and dead mosqui-
toes were removed from the containers. The containers
were then randomly placed back onto the shelves. All
mosquitoes that survived for five days were frozen and
counted as alive on day five post-capture. In 2009, both
the treated and the control village were sampled on the
same day by two separate field teams. In 2008, only one
village was sampled on each day (Additional file 1).
Mosquito processing
Mosquitoes were identified morphologically to species
[22,23] in the field insectary immediately following their
death. The abdomens were separated from the thoraxes
of all Anopheles spp. and placed into two separate
1.5 ml microfuge tubes containing the silica gel desic-
cant T.H.E. (EMD Chemicals, NJ, USA). The tubes were
labelled with the village, date of aspiration and hut loca-
tion, and all relevant information was recorded on
matching log sheets. Processed mosquitoes were shipped
back to Colorado State University for further molecular
analysis. DNA was extracted with the Qiagen DNeasy
kit (Qiagen Sciences, Maryland, USA) and a Qiacube
robot (Qiagen Sciences, Maryland, USA). Multiplex
polymerase chain reaction was used to molecularly iden-
tify members of the An. gambiae s.l. complex [24]. A
subset of twelve or fewer An. gambiae s.l. from each col-
lection day that died within one day of capture and con-
tained undigested blood at the time of processing had
their blood meals analysed by the multiplex polymerase
chain reaction to determine the source of blood [25].
Survivorship model and statistics
A generalized linear mixed (Glimmix) model was used
to assess the effects of IVM MDA on mosquito survi-
vorship. Mosquito survivorship results for each village at
each sampling date were classified by treatment
(whether or not they originated from a treatment or
control village), replicate (the three pairs of villages
sampled over the two field seasons), and phase. The
three phases are groups of sampling dates from each vil-
lage before MDA (phase 1), one to six days after MDA
(phase 2), and seven days or more after MDA (phase 3).
The one to six day grouping immediately after MDA
was chosen based on the differential survivorship curves
generated from the three replicates (Figure 1). Treat-
ment and phase were treated as fixed effects. Replicates
were treated as random effects with sample date nested
within replicate and phase. The model was fit by the
SAS Glimmix procedure using maximum likelihood esti-
mation with three Gaussian quadrature points (SAS
Institute, Cary, NC, USA). The percent survivorship of
mosquitoes was tested for interaction of treatment by
phase, and if significant, then post-tests were performed
to determine which treatment by phase groups signifi-
cantly differed from the others. The efficacy of IVM to
reduce mosquito survivorship would be reflected by a
significant drop in the treated village survivorship at the
phase 2 group compared to control and pre-treatment
groups.
Modelling the change in the basic reproductive number
of malaria due to ivermectin mass drug administrations
A linear calculation of the daily probability of survivor-
ship was determined from the five-day survivorship
values of An. gambiae s.l. captured before and after
MDA from all three replicates. These daily probability
of survivorship estimates were then inserted into an
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Figure 1 Percent survivorship of aspirated An. gambiae s.s.
grouped by treatment and phase. Percent survivorship of all
aspirated An. gambiae s.s. (N = 1265) held five days post-capture
from all three replicates. Standard error bars represent the percent
survivorship variation of all mosquitoes from each village grouped
within each treatment and phase.
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from Billingsley et al [21] with several minor modifica-
tions. The proportion of treated humans was not held
constant, but rather varied temporally based on MDA
coverage. It was assumed that once treated with drug,
humans remained mosquitocidal to feeding Anopheles
for six days. Output of this model was used as input for
an age-structured model [21] showing the relative
change in the basic reproductive number of malaria dur-
ing IVM treatment. A relative R0 < 1 indicates a
decrease in transmission, while relative R0 > 1 indicates
an increase in transmission and relative R0 = 1 indicates
no change.
Immature mosquito lifestages were assumed to have a
daily survival rate of 0.9. Based on the data estimated
from field-collected mosquitoes, it was assumed that
mosquitoes that imbibed blood from an untreated
human had a daily survival rate of 0.96, while mosquitoes
that fed on a treated human had a daily survival rate of
0.86 for 3 days post-feeding. To be conservative, it was
assumed that after feeding on a treated human, mosqui-
toes experienced a decrease in their daily survival rate for
three days post-feeding, after which they recovered to
untreated levels. An extrinsic incubation period of four-
teen days was used for the model. Age-specific fecundity
was not affected by IVM as was previously stated [21].
Results
Mosquito survivorship analysis
Figure 1 depicts the percent survivorship of An. gambiae
s.s. from all three replicates grouped by treatment and
phase. There is an observable reduction in An. gambiae
s.s. survivorship after IVM MDA (phase 2) in the treated
villages that lasts for six days. The survivorship of An.
gambiae s.s. in Ibel during phase 3 is low (Figure 1), but
this line only represents ten mosquitoes caught from
one collection (Additional file 1). A total of 1,265 An.
gambiae s.s. from three replicates were captured and
held for survivorship analysis. The model of estimated
mosquito survivorship for An. gambiae s.s. identified a
treatment by phase interaction, indicating that the dif-
ference between treated and control survivorship
depends on phase (F-value = 18.27, P < 0.0001) (Figure
2). In follow-up comparisons, treatment at phase 2 sig-
nificantly differed from control at phase 2 (t-value =
4.01, P = 0.0003), and it also significantly differed from
both treatment at phase 1, pre-MDA (t-value = 8.31, P
< 0.0001) and treatment at phase 3, seven days and after
IVM MDA (t-value = -4.61, P < 0.0001). The conclusion
of this analysis is that IVM MDA significantly reduced
the survivorship of An. gambiae s.s. for six days past the
date of the MDA.
Adequate numbers for survivorship analysis of An. ara-
biensis were only caught during the third replicate
(Damboucoye and Nathia, n = 153). There appears to be
a reduction in survivorship of An. arabiensis following
IVM MDA (Figure 3), but treatment by phase compari-
sons were not significantly different from each other
(F-value = 0.66, P = 0.5332). However, treatment alone
was significant (F-value = 7.01, P = 0.0191), therefore the
overall survivorship of An. arabiensis was lower in the
treated village compared to the control village (Figure 4).
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Figure 2 Glimmix model estimated percent survivorship of An.
gambiae s.s. grouped by treatment and phase. Glimmix model
estimated percent survivorship of all An. gambiae s.s. (N = 1265)
held five days post-capture from all three replicates. * Treatment by
phase was significant (F-value = 18.27, P < 0.0001). Treatment at
phase 2 significantly differed from control at phase 2 (t-value = 4.01,
P = 0.0003), treatment at phase 1 (t-value = 8.31, P < 0.0001), and
treatment at phase 3 (t-value = -4.61, P < 0.0001).
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Figure 3 Percent survivorship of aspirated An. arabiensis
grouped by treatment and phase. Percent survivorship of all
aspirated An. arabiensis (N = 153) held five days post-capture from
Nathia and Damboucoye. Standard error bars represent the percent
survivorship variation of all mosquitoes from each village grouped
within each treatment and phase.
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Almost all, 97.8% (136/139), of An. gambiae s.s. blood
meals that were analysed were from humans. Based on
this information it was assumed that almost all of the
An. gambiae s.s. held for the study had fed on humans.
However, only 75% (24/32) of analysed An. arabiensis
blood meals were from humans (Figure 5).
Modelling the effect of ivermectin treatment on malaria
transmission
Simulations indicate that MDA with IVM can signifi-
cantly reduce R0 for a short period of time after drug
administration (Figure 6A). Using the previously stated
assumptions and an ideal situation of 100% coverage, a
synchronized MDA of IVM results in an approximately
90% reduction in R0 immediately following MDA
(Figure 6A). After effective drug concentrations are
cleared from the blood of the human population, R0
rebounds to pre-treatment levels or slightly higher if no
further MDAs are performed. To keep relative R0 levels
at significantly lower levels, drug treatment must be
administered repeatedly. Less frequent treatments allow
for periods of control alternated with periods of no con-
trol (Figure 6A).
Due to the fluctuating nature of the control dynamics,
where R0 is changing on a daily basis, it is more infor-
mative to compare average relative R0 between different
treatment intervals. This can be easily calculated by
summing the area under the curve for both pre and
post-treatment scenarios. Under the ideal conditions of
100% coverage with treatment every week, mean R0 can
be reduced by 80%. Lower levels of coverage or less
frequent MDAs reduce the efficacy of this strategy, but
in all cases MDA resulted in some level of control
(Figure 6B).
Discussion
Previously published laboratory based evidence showed
that colonized An. gambiae s.s. is susceptible to IVM at
concentrations relevant to human pharmacokinetics after
a typical MDA [13], and that colonized An. gambiae s.s.
fed on IVM-treated humans one day post-treatment had
reduced survivorship [15]. The current study now
demonstrates that routine MDA of IVM to people signifi-
cantly reduces the survivorship of wild An. gambiae s.s.
for up to six days post MDA. This six day lethal effect is
longer than the two days observed from Kobylinski et al.
[13], and this effect occurs despite incomplete MDA cov-
erage in treated villages. Three field replicates were per-
formed over space and time in different villages to make
this study a rigorous assessment of the effects of IVM
MDA on An. gambiae s.l.
There were no significant differences in An. arabiensis
treatment by phase survivorship (F-value = 0.66, P =
0.5332) but this was almost certainly due to sampling, in
that adequate numbers (n = 153) for survivorship analysis
were only captured in the third replicate MDA. The third
replicate MDA was performed in October 2009, toward
the end of the rainy season when An. arabiensis is more
prevalent [20]. There was a 38% reduction in mosquito
survivorship from phase 2 treatment collections com-
pared to phase 2 control collections (Figure 4). The fact
that treatment alone was significant (F-value = 7.01, P =
0.0191), means that the overall survivorship of An. ara-
biensis was lower in the treated village compared to the
control village (Figure 4). Furthermore, only 75% (24/32)
of An. arabiensis blood meals were from humans
(Figure 5), which reduces the probability that mosquitoes
held for survivorship analysis may have ingested an IVM-
containing blood meal. Fritz et al [26] reported that colo-
nized An. gambiae s.s. and colonized An. arabiensis have
almost identical susceptibility to IVM. When these data
are considered together, it is reasonable to assume that
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Figure 4 Glimmix model estimated percent survivorship of An.
arabiensis grouped by treatment and phase. Glimmix model
estimated percent survivorship of all An. arabiensis (N = 153) held
five days post-capture from Nathia and Damboucoye. *Treatment
was significant (F-value = 7.01, P = 0.0191).
An. gambiae s.s. An. arabiensis
n = 139 n = 32
Human
Cow
Dog/Human
Figure 5 Percent composition of blood meal sources of
aspirated An. gambiae s.l. The percent blood meal sources of a
subset of An. gambiae s.s. (n = 139) and An. arabiensis (n = 32)
aspirated from all five villages in 2008 and 2009.
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shown to be as susceptible to IVM MDA as wild An.
gambiae s.s.
Based on clinical records, 84.2% (203/241) of people in
Damboucoye and 82.1% (311/379) of people in Ndebou
were treated with IVM during these two MDAs. Preg-
nant women and children under 90 cm did not receive
the drug, following the manufacturer guidelines. Mos-
quitoes that were held for survivorship analysis for five
days had completely digested their blood meals, which
made it impossible to detect IVM from individual mos-
q u i t o e s .Y e ti ti si m p r e s s i v et h a tm o s q u i t os u r v i v a lw a s
still significantly reduced despite not knowing whether
any one mosquito fed on a treated person. Incomplete
coverage may actually be beneficial to the overall con-
cept of repeated IVM MDAs for malaria control in that
it may provide a refugia of untreated human hosts for
mosquitoes to feed on which could reduce the likeli-
hood of IVM resistance development in the mosquito
population.
A
B
Figure 6 Predicted relationship between MDA and changes in malaria R0. Relative malaria R0 values < 1.0 indicate reduction in transmission
potential, values > 1.0 indicate increase in transmission potential, while 1.0 (green line in 6A) indicates no change. A) Ideal situation of 100%
coverage with MDA, administered every 7 (black), 14 (blue) or 30 (red) days. B) Average relative R0 for a range of MDA coverage levels (10% to
100%) and treatment regimes (every 7 to 30 days).
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Page 6 of 10Of people accounted, 78.2% (903/1,155) utilized ITNs
across the four villages surveyed in 2009. Even with high
ITN coverage, human blood fed An. gambiae s.s. and
An. arabiensis were frequently collected from the inside
of huts, demonstrating that ITNs have limitations in
preventing Anopheles from feeding on people in huts.
Exophagic and exophilic malaria vectors also comprise
an important part of the malaria transmission cycle in
this study area; Anopheles funestus group mosquitoes
are almost twice as likely to blood feed outdoors than
indoors [20], and Anopheles nili tend to be exophilic or
immediately exit huts after biting [20,27]. ITNs may
reduce malaria transmission by exophagic vectors
[28-30], but their primary efficacy is against endophagic
vectors. It has also been shown that ITNs may shift vec-
tor host seeking times to earlier in the evening when
people will not be sleeping under an ITN [31]. IRS will
only affect the survivorship of endophilic vectors that
c o n t a c tt h es p r a y e ds u r f a c e s ,a n di ti sb e l i e v e dt h a tt h e
exophilic portion of the An. gambiae s.l. population led
to the failure of IRS to eliminate malaria transmission
during the Garki project [32]. Furthermore, a number of
malaria vectors will naturally feed at dusk and dawn,
when humans are less likely to be indoors and protected
by an ITN or by IRS. Ivermectin MDA may be one of
the few methods that can directly target these exopha-
gic, exophilic, and crepuscular-feeding malaria vectors,
and should integrate well with the employment of exist-
ing in-home control methods like ITNs and IRS.
Ivermectin has a different mode of action from the
insecticide classes currently used for ITNs and IRS (i.e.,
carbamates, pyrethroids, and organochlorines) [3], in
that it agonizes the glutamate-gated chloride anion
channels found in invertebrate postsynaptic neurons and
neuromuscular junctions [33,34]. This action hyperpo-
larizes the neurons and muscle fibers, leading to flaccid
paralysis and insect death [35-37]. Once or twice yearly
IVM MDA has been occurring in this region for over
fifteen years [17], so the fact that a reduction in survi-
vorship of An. gambiae s.s. was still detectable is a pro-
mising sign that resistance by Anopheles spp. may be
slow to develop against this drug. Furthermore, the
novel mode of action of ivermectin compared the cur-
rently used insecticides for malaria control should
potentially minimize issues of cross-resistance where
IVM MDA may be used in combination with IRS and
ITNs.
Anopheles gambiae s.s. often requires two blood meals
to complete its initial gonotrophic cycle [38,39] and
thereafter will often take multiple blood meals per gono-
trophic cycle [40-42] and feeds almost exclusively on
humans (Figure 5) [20]. These blood feeding characteris-
tics, coupled to the fact that the extrinsic incubation
period for Plasmodium spp. is 9-14 days, means that
most malaria transmission by An. gambiae s.s. will
occur only after Plasmodium parasite-harbouring mos-
quitoes have taken multiple non-sporozoite transmitting
blood meals from humans [21,43]. If human population
clusters were simultaneously treated with IVM MDA,
then most adult An. gambiae s.s. in the MDA area
would imbibe a concentration of IVM that would reduce
their survivorship. The predicted effect has the potential
to temporarily shift the An. gambiae s.s. population age
structure, which would reduce the reservoir of adult
sporozoite-transmitting An. gambiae s.s. in the MDA
area. The low sporozoite rate in the resulting mosquito
population would temporarily reduce the basic repro-
ductive number (R0) of malaria below the base number
for approximately eleven days post IVM MDA. Current
IVM MDAs for onchocerciasis control in Africa are per-
formed only once or twice per year, and do not always
coincide with local malaria transmission seasons. Such
current applications would not be expected to lower
malaria transmission long enough to see any noticeable
reductions of parasite prevalence, intensity or disease in
people. Indeed, malaria is hyperendemic in APOC-
control areas of south-eastern Senegal despite IVM
MDAs for more than 15 years. However, if IVM MDA
is administered repeatedly, R0 can be reduced for an
extended period of time.
This model, like all models, makes assumptions that
may not be realistic in nature, such as homogeneous
mosquito biting, no spatial structure, and the lack of
density-dependent effects. However, the model results
a r ec o n s e r v a t i v e ,s i n c ei to n l yi n c o r p o r a t e st h ed i r e c t
IVM-related mortality effect observed in the field. Koby-
linski et al [13] demonstrated in the lab that multiple
sub-lethal IVM containing blood meals compounds
mosquito mortality, but the model assumes complete
recovery of surviving mosquitoes three days after ingest-
ing an IVM-containing blood meal. Kobylinski et al [13]
also demonstrated that the re-blood feeding frequency
and blood digestion of An. gambiae s.s. are delayed after
imbibing relevant IVM concentrations. Finally, Fritz
et al [26] and personal observations have witnessed
mosquito knockdown effects immediately after drug
ingestion. All of these negative sub-lethal effects would
probably lead to a further reduction in An. gambiae s.s.
survivorship in the field, due to desiccation, predation,
or insufficient nutrition, beyond that of outright mortal-
ity induced by IVM. Thus, it may be that the age-
structured model is an underestimate of the true effect
of IVM MDA on malaria transmission.
The age-structured model predicts that strategically
administered, repeated IVM MDAs would achieve sus-
tained reductions in malaria transmission. Such repeated
M D A sm a yo n l yb el o g i s t i c a l l yf e a s i b l ef o ra r e a sw i t h
seasonal malaria transmission, such as the Sahel, or in
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Page 7 of 10areas experiencing malaria epidemics. An expanded
IVM MDA regimen fits well with the idea of combating
polyparasitism in some of these same communities
[44,45]. Malaria and soil-transmitted helminths (STHs -
Ascaris lumbricoides, Trichuris trichiura, Strongyloides
stercoralis,a n dh o o k w o r m s )a r ec o - e n d e m i ca c r o s s
much of sub-Saharan Africa [46-50]. The annual/biann-
ual IVM MDAs for onchocerciasis control are not gen-
erally sufficient for controlling STHs because of
relatively rapid re-infections due to their transmission
dynamics [51-55]. Repeated IVM MDAs are likely to
result in reductions of the prevalence and intensities of
STHs in individuals receiving the drug [52-59], and
would increase the personal incentive to participate in
such MDAs. The combination of malaria and soil-
transmitted helminth infections can exacerbate anaemia,
resulting in worsened child development and more
adverse pregnancy outcomes than these diseases cause
on their own [60-64]. Therefore, the combined effects of
IVM MDA on multiple parasites could potentially
reduce anaemia in the human population which would
lead to an overall improvement in human health beyond
what would be expected from malaria control alone.
Future field work will need to be conducted to deter-
mine if repeated IVM MDAs can quantifiably reduce
malaria transmission and if the model created here is an
over or underestimate of what would occur in the field.
Important to this future work is determining whether a
logistically feasible IVM MDA interval can be devised
that would reduce malaria transmission below a critical
threshold and not foster IVM resistance in either Ano-
pheles vectors or human nematode parasites.
Conclusions
This study demonstrates that IVM MDA reduces the
survivorship of wild-caught An. gambiae s.s. for up to
six days post MDA and the modelled field data shows
that repeated IVM MDAs should result in a sustained
reduction of malaria transmission. Ivermectin MDA
would be both a novel insecticide class and delivery
method for reducing vector survivorship. It should also
affect exophagic, exophilic, and crepuscular-feeding
malaria vectors not normally targeted by malaria control
measures. Repeated IVM MDAs should concomitantly
reduce STH prevalence and intensities, which would
further benefit human health beyond that of malaria
control alone.
Additional material
Additional file 1: Number of mosquitoes captured by aspiration by
mosquito species, village, year, phase, and date. The number of
mosquitoes caught each aspiration collection by date and grouped by
phase. *Coll - number of aspiration collections performed per phase.
**Trtmt - whether or not a village was treated by IVM MDA. ***#ct -
number of each mosquito species caught that aspiration collection.
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